Quale modello nell'analisi farmacocinetica di studi di biodisponibilità e bioequivalenza?

Bollettino Chimico Farmaceutico

Volumn 137, Issue 3, 1998, Pages 69-73

  Marzo, A ^a   Ceppi Monti, N ^a  

^a IPAS SA   (Switzerland)

Author keywords

Bioavailability; Bioequivalence; Compartmental model; Guide line; Non compartmental model; Pharmacokinetic analysis

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL MODEL; PHARMACOKINETICS; TISSUE DISTRIBUTION;

AREA UNDER CURVE; MODELS, BIOLOGICAL; PHARMACOKINETICS; THERAPEUTIC EQUIVALENCY; TISSUE DISTRIBUTION;

EID: 0032015128     PISSN: 00066648     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Atkinson A.J., Ruo T.I., Frederiksen M.C. TIPS, 12, 96 (1991).
2. Gillespie W.R. Clin. Pharmacokin., 20, 253 (1991).
3. Calburn W.A. J. Clin. Pharmacol., 28, 879 (1988).
4. a edizione, 1995, pag. 83-96.
5. Meier J., Nüesch E., Schmidt R. Eur. J. Clin. Pharmacol., 7, 429 (1974).
6. Marzo A., Boll. Chim. Farm., 131, 139 (1992).
7. nd edition, 1982.
8. Clark B., Smith D.A., An introduction to pharmacokinetics Blackwell Scientific Publications, 2nd edition, London, 1986.
9. Note for Guidance: Investigation of bioavailability and bioequivalence. CPMP working party on efficacy of medicinal product. III/54/89 - EN - FINAL, December 1991.
10. U.S. Food and Drug Administration. Bioavailability and bioequivalence requirements. Federal Register, 42, 1638 (1977).
11. In vivo bioequivalence guidances / General information United States Pharmacopoeia XXIII, Supplementum, 5, 3490 (1996).
12. Marzo A., Balant L.P., Arzneim. Forsch., 45, 109 (1995).